free in Medical Technology
Navigation Links
free in Medical Technology
-Second Data Set Presented at MDS-
PARIS, June 9 /PRNewswire/ -- Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...
--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...
SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...
BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...
Infant Deaths Spur Hard-Hitting, System-Wide Hand Washing Campaign That Drives Culture Change, Saves Lives CHARLOTTE, N.C., Sept. 16 /PRNewswire/ -- Novant Health, one of the top 10 integrated health systems in the country, dramatically increased hand-washing compliance from ...
MONTERREY, Mexico, March 20 /PRNewswire/ -- Optimum Health Regeneration Center announced the successful treatment of an American family treated for pain management and impaired mobility. This New Mexico family, ranging in age from 52 to 78, all recorded significant improvements in reduced pain...
Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...
MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free ...
SWEDESBORO, N.J., Dec. 3 /PRNewswire/ -- Wedgewood Pharmacy has introduced the Refresh(TM) exchange-program, which lets veterinarians return expired custom-compounded medications for exchange, at no cost. The program is a compounding-pharmacy profession first. Through the program, the company ...
Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC) Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC study, demonstrate for the first time that peri-operative (pre and post surgery) FOLFO...
...provide to patients who are affected by Type 1 Gaucher disease," said Dr. Atul Mehta, Clinical Director of the Lysosomal Storage Disorders Unit, Royal free Hospital, London. "Velaglucerase alfa appears to be an excellent choice for Type 1 Gaucher patients. The prospect of having another treatment option a...
...ne patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months. This poster is available at www.celltherapeutics.com/investor_updates About (product) OPAXIO(TM) (paclitaxe...
... section for John Legend's MSG show. Even better, with each (RED)ZONE ticket purchase, shoppers will automatically receive a second ticket to the show free of charge. Additionally, a select number of fans seated in the (RED)ZONE section will be randomly selected to go backstage to personally meet Legend a...
...practices in the United States. Energy therapies come from many cultures and are based on ideas about natural energy fields. They aim to create a free flow of energy by clearing, balancing and stimulating the human energy system. Though energy therapies are not well understood or always embraced by t...
...ment period with pixantrone compared to other agents. These additional late responders are likely to have a positive impact on analyses of progression free and overall survival and will be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Exe...
...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do no...
...inflammatory disease, ankylosing spondylitis," said Jurgen Braun, MD, lead physician at the Rheumazentrum Ruhrgebiet, Professor of Rheumatology at the free University of Berlin, lead study investigator. "As seen in this study, the possibilities of this new anti-TNF-alpha therapy are encouraging for both t...
...ure through Day 50 (p-value 0.1177), orBec(R) did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66%...
...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...
... treatment cycle have responded according to standard Cheson criteria. Remissions appear to be durable without further treatment with a median relapse free interval of 13 months for the seven patients in the 0.06 mg/m(2) per day dose cohort reported at ASH in 2008(2). The most common adverse events (AEs) ...
...9 months) and the median duration of response for the 48 responders was 6.8 months (95% CI; 5.4-11.0 months). Nineteen responders remained progression free at 6 months(1). "We continue to see the potential of Afinitor in multiple types of cancer," said Alessandro Riva, MD, Executive Vice President, ...
...or women who received chemotherapy alone. The hazard ratios for progression free survival and overall survival were 0.342 (p< 0.0001) and 0.348 (p=0.0005...h chemotherapy. "The improvement in overall survival and progression free survival together with the responses seen in this study are promising. We d...
...nd the trial and compare very favorably with historical data with chemotherapy alone. Recent analysis also shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months, an additional promising early result. Patient dosing a...
... proprietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimized for administration via an Investigat...L-CsA formulation is based on an artificial lung surfactant carrier. It is free of any irritating organic solvents and consists of unilamellar liposomes of...
...in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be complet...
...da, on 35 study patients over approximately 36 months, the survival rate for 97 percent of those patients was two years and the three-year progression free survival rate was 86 percent. Research was supervised by George Yoo, M.D., chief medical officer and member of the Head and Neck Cancer Multidisc...
...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...
...he long term loco-regional control rate of 100% combined with the very high percentage of patients in the mid and high dose groups that remain disease free at up to 36 months from treatment is very encouraging. As a result, OncoVEX GM-CSF clearly warrants further investigation in this setting. " ...
...ts included. These variations can mean the difference between being seizure free and suddenly having a seizure while driving on the freeway," said Dr. Brien...gistered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv . 05DC09-0022 ...
--First of 2 data sets to be released-- PARIS, June 8 /PRNewswire/ -- Results from two randomized, active-controlled clinical trials in patients with blepharospasm and cervical dystonia -- one placebo-controlled spasticity trial and one upper limb spasticity trial -- were presented at the ...
SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...
BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...
Infant Deaths Spur Hard-Hitting, System-Wide Hand Washing Campaign That Drives Culture Change, Saves Lives CHARLOTTE, N.C., Sept. 16 /PRNewswire/ -- Novant Health, one of the top 10 integrated health systems in the country, dramatically increased hand-washing compliance from ...
Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
- PFS data from Neuradiab(TM) compares favorably to data from other technologies - TSX: BMR TORONTO, July 17 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today release...MONTERREY, Mexico, March 20 /PRNewswire/ -- Optimum Health Regeneration Center announced the successful treatment of an American family treated for pain management and impaired mobility. This New Mexico family, ranging in age from 52 to 78, all recorded significant improvements in reduced pain...
Phase II Investigational Trial Published in CANCER: the Journal of the American Cancer Society SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC ; MTAX) announced today that results of a phase II clinical study, published in the jou...
MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Fundamental Applied Biology, Inc. (FAB) announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase IIB grant from the National Science Foundation. The $500,000 grant will be used to continue to develop FAB's cell-free ...
SWEDESBORO, N.J., Dec. 3 /PRNewswire/ -- Wedgewood Pharmacy has introduced the Refresh(TM) exchange-program, which lets veterinarians return expired custom-compounded medications for exchange, at no cost. The program is a compounding-pharmacy profession first. Through the program, the company ...
Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC) Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of the randomized phase III EORTC 40983 Intergroup study, or EPOC study, demonstrate for the first time that peri-operative (pre and post surgery) FOLFO...
...provide to patients who are affected by Type 1 Gaucher disease," said Dr. Atul Mehta, Clinical Director of the Lysosomal Storage Disorders Unit, Royal free Hospital, London. "Velaglucerase alfa appears to be an excellent choice for Type 1 Gaucher patients. The prospect of having another treatment option a...
...ne patients. Two patients remain without evidence of disease progression, and six patients were alive at time of data presentation. Median progression free survival was 3.3 months. This poster is available at www.celltherapeutics.com/investor_updates About (product) OPAXIO(TM) (paclitaxe...
... section for John Legend's MSG show. Even better, with each (RED)ZONE ticket purchase, shoppers will automatically receive a second ticket to the show free of charge. Additionally, a select number of fans seated in the (RED)ZONE section will be randomly selected to go backstage to personally meet Legend a...
British Woman Celebrates a Year of Living Cancer-Free
...r (TaNK) cells as a treatment for leukemia. Her doctors at the Royal free Hospital in London recommended this experimental therapy after two years of...e key to a new type of advanced cancer therapy. Doctors at the Royal free injected Ms. Scott with natural killer (NK) cells taken from her daughter, ......practices in the United States. Energy therapies come from many cultures and are based on ideas about natural energy fields. They aim to create a free flow of energy by clearing, balancing and stimulating the human energy system. Though energy therapies are not well understood or always embraced by t...
Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
... of its product candidate Fluidosomes(TM)-tobramycin, whose unique microbiological profile sets it apart from other antibiotic formulations (including free tobramycin). Axentis Pharma (Switzerland) announced today that the Office of Orphan Products Development of the US Food and Drug Administration...Dry Mouth Linked to Prescription and Over the Counter Drugs
...mpt to increase salivary production by drinking water; less than 58 percent say patients try taking over-the-counter saliva substitutes, chewing sugar free gum, or sucking on hard candy; and More than 60 percent of those surveyed consider diagnosing a patient with xerostomia after he or she exhibi...Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
... velaglucerase alfa ahead of commercial availability in the US. Under the conditions of the treatment protocol, Shire would provide velaglucerase alfa free of charge initially, in order to provide access to patients as quickly as possible. Velaglucerase alfa is made with Shire's proprietary technol......ment period with pixantrone compared to other agents. These additional late responders are likely to have a positive impact on analyses of progression free and overall survival and will be provided to the U.S. Food and Drug Administration during the 120-day update," stated James A. Bianco, M.D., Chief Exe...
School of Dentistry Studies Link Between Oral Health and Memory
...ions for health of our aging populations," Crout said. "With rates of Alzheimer's skyrocketing, imagine the benefits of knowing that keeping the mouth free of infection could cut down on cases of dementia." The research builds on an ongoing study of West Virginians aged 70 and older. Working with the...CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
... - 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial - BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corpora......for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do no...
...inflammatory disease, ankylosing spondylitis," said Jurgen Braun, MD, lead physician at the Rheumazentrum Ruhrgebiet, Professor of Rheumatology at the free University of Berlin, lead study investigator. "As seen in this study, the possibilities of this new anti-TNF-alpha therapy are encouraging for both t...
...ure through Day 50 (p-value 0.1177), orBec(R) did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66%...
...for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...
... treatment cycle have responded according to standard Cheson criteria. Remissions appear to be durable without further treatment with a median relapse free interval of 13 months for the seven patients in the 0.06 mg/m(2) per day dose cohort reported at ASH in 2008(2). The most common adverse events (AEs) ...
...9 months) and the median duration of response for the 48 responders was 6.8 months (95% CI; 5.4-11.0 months). Nineteen responders remained progression free at 6 months(1). "We continue to see the potential of Afinitor in multiple types of cancer," said Alessandro Riva, MD, Executive Vice President, ...
...or women who received chemotherapy alone. The hazard ratios for progression free survival and overall survival were 0.342 (p< 0.0001) and 0.348 (p=0.0005...h chemotherapy. "The improvement in overall survival and progression free survival together with the responses seen in this study are promising. We d...
...nd the trial and compare very favorably with historical data with chemotherapy alone. Recent analysis also shows the median progression free survival of the patients enrolled in the first part of the study was 7.4 months, an additional promising early result. Patient dosing a...
IBM and EU Partners Create a Better Way to Fight AIDS Virus
...nificantly improves prediction of the right combination of drugs that works for the maximum amount of time." These innovations are being provided as a free tool that can help extend the lives of millions of people who are the victims of this disease. The system's predictions are near 76% accurate, ...... proprietary liposomal technology we created an inhaled formulation that is free from irritating solvents and optimized for administration via an Investigat...L-CsA formulation is based on an artificial lung surfactant carrier. It is free of any irritating organic solvents and consists of unilamellar liposomes of...
...in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective (or increase remission rates or progress free survival) for treatment of relapsed or refractory aggressive NHL as determined by the FDA, the possibility that the NDA submission will not be complet...
...da, on 35 study patients over approximately 36 months, the survival rate for 97 percent of those patients was two years and the three-year progression free survival rate was 86 percent. Research was supervised by George Yoo, M.D., chief medical officer and member of the Head and Neck Cancer Multidisc...
GreenBytes Wards Off Germs and Costly Computer Repairs
...nce to function properly. GreenBytes provides this type of preventative service, and we specialize in Germ-Free cleaning, too." GreenBytes offers free service demonstrations to illustrate the condition of home and office equipment. Appointments are available through the company's Authorized Preventat...Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
...trials, 3.3% of patients randomized to 400 mg/day of Vimpat(R) were seizure free throughout the 12-week maintenance phase, vs. 0.9% of placebo patients. Seizure free days increased by 8% with 200 mg/day of Vimpat(R) and by 12% with 400 mg/da......for the fiscal quarter year ended April 4, 2009, filed with the Securities and Exchange Commission (" SEC ") on May 6, 2009, which may be obtained for free at the SEC's website at www.sec.gov . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not...
...he long term loco-regional control rate of 100% combined with the very high percentage of patients in the mid and high dose groups that remain disease free at up to 36 months from treatment is very encouraging. As a result, OncoVEX GM-CSF clearly warrants further investigation in this setting. " ...
...ts included. These variations can mean the difference between being seizure free and suddenly having a seizure while driving on the freeway," said Dr. Brien...gistered journalists can access video, audio, text, graphics and photos for free and unrestricted use at http://www.mediaseed.tv . 05DC09-0022 ...
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
...Vanda files annual, quarterly and special reports, proxy and information statements, and other information with the SEC. These documents are available free of charge at the SEC's web site at www.sec.gov or from Vanda at www.vandapharma.com . STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY ...Other TagsEPHEPHEPHEPHEPHEPHEPHLiClNGALNGALNGALLambLambsheetsheetOther Contentsorthopedicsimperfectaosteoarthritisosteoarthritisosteoarthritisosteoarthritisosteomaosteomyelitis
(Date:11/30/2009)... the state of Antarctica,s climate and its relatio...is week (Tuesday 1 December) by the Scientific Com... Antarctic Climate Change and the Environment pre...identifies areas for future scientific research, a...rs have about Antarctic melting, sea-level rise an...
(Date:11/30/2009)...rgh team overcame a major hurdle plaguing the deve...lead to more efficient catalysts used to produce h...earchers reported Nov. 29 in Nature Materials th...y in metallic nanoparticles, the vaunted next-gene...treme heat. , Gtz Veser, an associate professor ...
(Date:11/30/2009)...perimental Biology are pleased to announce that D...he Scientifique (CNRS) in the Universit de Nice-So...Outstanding Paper Prize. ,The prize is awarded in ...ntended to encourage young scientists, says Hans ...t ,we truly appreciate when authors submit their v...
Breaking Biology News(10 mins):First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Boston University scientists first to see RNA network in live bacterial cells 10489 1Boston University scientists first to see RNA network in live bacterial cells 10489 2Synthetic cells shed biological insights while delivering battery power 10487 1Synthetic cells shed biological insights while delivering battery power 10487 2Biochemical on switch could solve protein purification challenge 10485 1Biochemical on switch could solve protein purification challenge 10485 2(Date:12/1/2009)... First Mercury Financial...he "Company") announced today that on November 30,...cash dividend of $0.025 per share, to be paid Dece...se of business on December 15, 2009. ,, Abou... Mercury Financial Corporation provides insurance ...
(Date:12/1/2009)...isolating behaviors jump from friend to friend , ...ew study suggests that lonely people attract fello...too. , "Loneliness can spread from person to pe...n," said James H. Fowler, co-author of the study p...Personality and Social Psychology , and professor ...
(Date:12/1/2009)...s of any medical, legal or business requiring dict...lief this week with the release of ,DictateOnTheGo...r the holiday weekend, allows anyone required to d...ickly and seamlessly using just the iPhone 3G devi... 2009 -- The iPhone App, released by Florida based...
(Date:12/1/2009)... Air Products (NYSE: A...nounced sale of the assets of its polyurethane pre...74; and Versathane® tradenames to COIM USA In...e chemicals producer COIM SpA. ,, Included in ...in Paulsboro, N.J. Terms of the agreement are not ...
(Date:12/1/2009)...wire/ -- Abrazo Media Relations-- The Center for P...pedsorthopaedics.com ) located in Mesa, Arizona an... Hunt Udall to its practice. ,, Dr. Udall is t...after recently completing his fellowship training ...re he focused on adult and pediatric orthopaedic s...
Breaking Medicine News(10 mins):Health News:Loneliness May Be Catching 2Health News:Loneliness May Be Catching 3Health News:Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go' 2Health News:Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA 2Health News:Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy 2[0] First Mercury Financial Corporation Declares Dividend[0] Loneliness May Be Catching[0] Medical and Legal Professionals Find Relief Leveraging Apple iPhone App for Dictation and Transcription 'On the Go'[0] Air Products Completes Sale of Polyurethane Pre-Polymers Business to COIM USA[1] Orthopaedic Surgeon Dr. J. Hunt Udall Joins the Center for Pediatric Orthopaedics and Scoliosis as One of Few Trained Doctors to Perform Minimally Invasive Hip Arthroscopy
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |